GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Piotroski F-Score

Huadong Medicine Co (SZSE:000963) Piotroski F-Score : 8 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Huadong Medicine Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Huadong Medicine Co's Piotroski F-Score or its related term are showing as below:

SZSE:000963' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 8

During the past 13 years, the highest Piotroski F-Score of Huadong Medicine Co was 8. The lowest was 3. And the median was 6.


Huadong Medicine Co Piotroski F-Score Historical Data

The historical data trend for Huadong Medicine Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Piotroski F-Score Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 5.00 4.00 5.00

Huadong Medicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.00 6.00 5.00 8.00

Competitive Comparison of Huadong Medicine Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 678.54 + 755.222 + 649.814 + 862.412 = ¥2,946 Mil.
Cash Flow from Operations was 2267.897 + 227.534 + 1679.939 + -484.523 = ¥3,691 Mil.
Revenue was 10270.813 + 10009.186 + 10229.252 + 10410.809 = ¥40,920 Mil.
Gross Profit was 3144.119 + 3215.171 + 3478.954 + 3334.412 = ¥13,173 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(32115.201 + 32956 + 33992.686 + 33509.362 + 34467.844) / 5 = ¥33408.2186 Mil.
Total Assets at the begining of this year (Mar23) was ¥32,115 Mil.
Long-Term Debt & Capital Lease Obligation was ¥602 Mil.
Total Current Assets was ¥19,212 Mil.
Total Current Liabilities was ¥10,918 Mil.
Net Income was 636.206 + 640.9 + 517.744 + 755.285 = ¥2,550 Mil.

Revenue was 9265.385 + 9660.543 + 9856.08 + 10114.531 = ¥38,897 Mil.
Gross Profit was 2936.91 + 2897.089 + 3180.412 + 3323.807 = ¥12,338 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(28436.894 + 28760.973 + 30662.573 + 31192.203 + 32115.201) / 5 = ¥30233.5688 Mil.
Total Assets at the begining of last year (Mar22) was ¥28,437 Mil.
Long-Term Debt & Capital Lease Obligation was ¥783 Mil.
Total Current Assets was ¥18,315 Mil.
Total Current Liabilities was ¥10,628 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Huadong Medicine Co's current Net Income (TTM) was 2,946. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Huadong Medicine Co's current Cash Flow from Operations (TTM) was 3,691. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=2945.988/32115.201
=0.09173189

ROA (Last Year)=Net Income/Total Assets (Mar22)
=2550.135/28436.894
=0.08967699

Huadong Medicine Co's return on assets of this year was 0.09173189. Huadong Medicine Co's return on assets of last year was 0.08967699. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Huadong Medicine Co's current Net Income (TTM) was 2,946. Huadong Medicine Co's current Cash Flow from Operations (TTM) was 3,691. ==> 3,691 > 2,946 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=602.39/33408.2186
=0.01803119

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=782.833/30233.5688
=0.02589284

Huadong Medicine Co's gearing of this year was 0.01803119. Huadong Medicine Co's gearing of last year was 0.02589284. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=19212.283/10918.318
=1.75963761

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=18314.948/10627.556
=1.72334524

Huadong Medicine Co's current ratio of this year was 1.75963761. Huadong Medicine Co's current ratio of last year was 1.72334524. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Huadong Medicine Co's number of shares in issue this year was 1750.023. Huadong Medicine Co's number of shares in issue last year was 1750.371. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=13172.656/40920.06
=0.32191194

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=12338.218/38896.539
=0.31720606

Huadong Medicine Co's gross margin of this year was 0.32191194. Huadong Medicine Co's gross margin of last year was 0.31720606. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=40920.06/32115.201
=1.27416484

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=38896.539/28436.894
=1.36781953

Huadong Medicine Co's asset turnover of this year was 1.27416484. Huadong Medicine Co's asset turnover of last year was 1.36781953. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+0
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Huadong Medicine Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Huadong Medicine Co  (SZSE:000963) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Huadong Medicine Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines